CDK6 and laryngotracheoesophageal cleft: Univariable survival analysis did not show statistically significant associations of survival with gender and clinical HR stage (M + , residual disease; Fig. 3a–d), LC/A histology, nuclear β-catenin accumulation, i17q, AKT1-3 mutations, CDK6 gains, or monosomy 6 as well as clinical risk and therapy regimen (Online Resource Figs. 9–11).